Literature DB >> 16477633

Rapid induction of apoptosis in B-cell lymphoma by functionally isolated human antibodies.

Johan Fransson1, Ulla-Carin Tornberg, Carl A K Borrebaeck, Roland Carlsson, Björn Frendéus.   

Abstract

Novel panning and screening methodology was devised to isolate high affinity human recombinant scFv antibody fragments with functionally associated properties in B lymphoma cells. The approach was used to generate a panel of apoptosis-inducing antibodies specific for antigens differentially expressed in B lymphoma vs. T leukaemia cells. The selections resulted in an antibody pool with near perfect selectivity (>99%) for the B lymphoma target cells. Randomly picked clones (72) revealed 7 unique antibody genotypes. Six of these rapidly induced apoptosis in target cells. Following the conversion to full IgGs, the antibodies were shown to be specific for HLA-DR/DP, the B-cell receptor mu chain and for CD54/ICAM-1. The latter receptor was not previously associated with apoptotic properties in B-cell lymphomas. Anti-ICAM-1 IgG induced apoptosis in a broad range of B lymphoma cell lines and were shown by immunohistochemistry to bind strongly to B lymphoma tissue obtained from 5 different B lymphoma patients. The recombinant IgG antibodies had affinities in the subnanomolar (0.3 nM) to nanomolar (3 nM) range. The described technology is generally applicable for the rapid isolation of high affinity human antibodies with specificity for differentially expressed cell surface receptors with intrinsic negative or positive signalling properties from naïve phage libraries. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16477633     DOI: 10.1002/ijc.21829

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Serum concentrations of apoptosis-associated molecules in septic children with leukemia, neutropenia and fever.

Authors:  Jesus Reyna-Figueroa; Alfredo Lagunas-Martínez; Patricia Galindo-Delgado; María Fernanda Fernández-Bautista; Paola Guadalupe Castro-Oteo; Pilar Martínez-Matsumoto; Erika Melchy Perez; Yvonne Rosenstein; Ana Elena Limón-Rojas; Federico Javier Ortiz-Ibarra; Vicente Madrid-Marina
Journal:  Int J Hematol       Date:  2017-01-31       Impact factor: 2.490

Review 2.  Ligandomics: a paradigm shift in biological drug discovery.

Authors:  Wei Li; Iok-Hou Pang; Mario Thiego F Pacheco; Hong Tian
Journal:  Drug Discov Today       Date:  2018-01-08       Impact factor: 7.851

3.  Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy.

Authors:  Katja Klausz; Michael Cieker; Christian Kellner; Thies Rösner; Anna Otte; Steffen Krohn; Anja Lux; Falk Nimmerjahn; Thomas Valerius; Martin Gramatzki; Matthias Peipp
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

4.  A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma.

Authors:  Stina Wichert; Gunnar Juliusson; Åsa Johansson; Elisabeth Sonesson; Ingrid Teige; Anna Teige Wickenberg; Björn Frendeus; Magnus Korsgren; Markus Hansson
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

5.  Deep Mining of Complex Antibody Phage Pools Generated by Cell Panning Enables Discovery of Rare Antibodies Binding New Targets and Epitopes.

Authors:  Anne Ljungars; Carolin Svensson; Anders Carlsson; Elin Birgersson; Ulla-Carin Tornberg; Björn Frendéus; Mats Ohlin; Mikael Mattsson
Journal:  Front Pharmacol       Date:  2019-07-30       Impact factor: 5.810

6.  Function-first antibody discovery: Embracing the unpredictable biology of antibodies.

Authors:  Björn Frendéus
Journal:  Oncoimmunology       Date:  2013-05-20       Impact factor: 8.110

7.  Accelerating target deconvolution for therapeutic antibody candidates using highly parallelized genome editing.

Authors:  Jenny Mattsson; Ludvig Ekdahl; Fredrik Junghus; Ram Ajore; Eva Erlandsson; Abhishek Niroula; Maroulio Pertesi; Björn Frendéus; Ingrid Teige; Björn Nilsson
Journal:  Nat Commun       Date:  2021-02-24       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.